It is now thirteen years since Hertz and Roberts (1942) introduced radioactive iodine in the treatment of thyrotoxicosis, and in the succeeding years it has increasingly established itself in the therapy of this condition and has been widely used in the United States of America. We have previously recorded our experience in this country in a small series of cases (Blomfield et al., 1951, 1953; ...

A 55-year-old female patient presented to the endocrine clinic with Grave’s disease. She was initially treated with carbimazole. After an early relapse, a decision was made to proceed with radioactive iodine therapy. Four days after radioiodine administration, she presented to the emergency department with chest tightness and dyspnea due to heart failure. Biochemistry revealed thyrotoxicosis an...

Radioactive iodine (1311) has a part to play in the therapy of two thyroid disorders, carcinoma and thyrotoxicosis, by virtue of the selective concentration of it which occurs in functioning thyroid cells. The latter represent the only significant site of concentration of the iodide ion in the body, this occurring because of the necessity to incorporate iodine into the molecule of the thyroid h...

Radioactive iodine ((131)I) targets the thyroid gland and has been proven to play an effective role in the treatment of differentiated papillary and follicular cancers. Simultaneously, this radioisotope hones in on the salivary glands where it is concentrated and secreted into the saliva. Dose related damage to the salivary parenchyma results from the (131)I irradiation. Salivary gland swelling...

There are limited treatment options for patients with radioactive iodine refractory, progressive differentiated thyroid cancer. Although there is consensus that multikinase inhibitor therapy should be considered in patients with progressive disease with considerable tumor load or symptomatic disease, uncertainty exists on the optimal timing to treat with a multikinase inhibitor, especially for ...

© Translational Andrology and Urology. All rights reserved. Transl Androl Urol, 2017;6(S3) tau.amegroups.com amount of 125I, reaction time, pH, and reaction volume on the labeling rate of the 125I-RSOAds-hTERT/PSA oncolytic adenovirus marker were measured. Radioactive oncolytic adenoviruses were isolated and purified by column chromatography; the radiochemical purities of the 125I-RSOAds-hTERT/...

Iodine radioisotopes are released into the environment by the nuclear industry and medical research institutions using radioactive materials. The (129)I(-) anion is one of the more mobile radioactive species due to a long half-life, and it is a great challenge to design long-term management solutions for such radioactive waste. In this study, a new adsorbent structure with the potential to effi...

BACKGROUND The purpose of this study was to examine the incidence of sialadenitis and xerostomia within a year after radioactive iodine administration for thyroid remnant ablation after preparation with recombinant human thyroid-stimulating hormone (rhTSH) or levothyroxine (LT4 ) withdrawal. METHODS The study has included 121 patients, divided into 4 groups: group A (rhTSH = 100 mCi), group B...

Dedifferentiation of follicular cells is a central event in resistance to radioactive iodine and patient mortality in papillary thyroid carcinoma (PTC). We reveal that platelet derived growth factor receptor alpha (PDGFRα) specifically drives dedifferentiation in PTC by disrupting the transcriptional activity of thyroid transcription factor-1 (TTF1). PDGFRα activation dephosphorylates TTF1 cons...